There is provided a novel series of analogues of glucose-dependentinsulinotropic polypeptidecompounds, pharmaceutical compositions containing said compounds, and the useof said compoundsas GIP-receptor agonists or antagonists for treatment of GIP-receptor mediatedconditions, such asnon-insulin dependent diabetes mellitus and obesity.